VRTX vs GILD
VRTX and GILD side by side — valuation & fundamentals (public data).
Key statistics
| Metric | VRTXVERTEX PHARMACEUTICALS INC / MA | GILDGILEAD SCIENCES, INC. |
|---|---|---|
| Market cap | $122.73B | $164.76B |
| P/E (TTM) | 28.7 | 18.1 |
| P/B | 6.34 | 7.01 |
| P/S | 10.2x | 5.6x |
| Dividend yield | — | 2.43% |
| Revenue | $12.22B(TTM) | $29.74B(TTM) |
| Revenue growth (YoY) | 8.9% | 2.4% |
| Net income | $4.34B(TTM) | $9.22B(TTM) |
| Earnings growth (YoY) | 838.1% | 1672.9% |
| EPS, diluted | $16.85(TTM) | $7.35(TTM) |
| EBIT margin | 34.8% | 34.0% |
| ROE | 20.4% | 36.2% |
| ROIC | 25.4% | 21.6% |
| 1y total return | +3.2% | +19.0% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: VRTX vs GILD
| Metric | VRTX | GILD |
|---|---|---|
| End value | $61.4K | $20.6K |
| Total return | +514.1% | +105.7% |
| CAGR | +19.2% | +7.2% |
| Volatility | 33.0% | 25.7% |
| Sharpe | 0.58 | 0.25 |
| Sortino | 0.86 | 0.37 |
| Max drawdown | -41.6% | -36.0% |
Based on 2600 common trading days, 2016-03-28 → 2026-07-29 · risk-free 3.83% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)